glp-1 news november 6 2025 ISPOR 2025: Exploring reasons for discontinuation 🚨 Breaking News in Obesity

What commercial factors are supporting current market adoption

The higher-dose semaglutide formulation for obesity (Wegovy, 2.4 mg weekly) can produce 10-15% weight loss, while diabetes doses typically yield more modest reductions

See our GLP-1 weight loss plan online and Meet Your Provider

TREATMENT OF CARDIOMETABOLIC DISEASES ASKS FOR SPECIFICALLY DESIGNED DELIVERY DEVICES Today, there are more than two dozen therapeutic candidates in the GLP-1 drug class undergoing clinical research

indicated that GLP-1RAs treatment might increase the risk of thyroid cancer, with the risk demonstrating an upward trend with prolonged usage of the medication (13 years and longer) [4]

GLP-1s and the opportunities for nutrient intake Speaking at the NutraIngredients Weight Management Summit in February, Rachel Jones, senior vice president and chief product innovation and science officer at GNC, previewed the studys results